Page last updated: 2024-10-23

aztreonam and Diabetes Mellitus, Type 2

aztreonam has been researched along with Diabetes Mellitus, Type 2 in 1 studies

Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
De Almeida Torres, N1
Morales Junior, R1
Bueno Lopes, LF1
Zeigler, R1
Everson Uip, D1

Other Studies

1 other study available for aztreonam and Diabetes Mellitus, Type 2

ArticleYear
Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis.
    Journal of infection in developing countries, 2023, 06-30, Volume: 17, Issue:6

    Topics: Acute Disease; Aged; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Diabetes Mellitus, Type 2; Drug

2023